S1), suggesting that the modulation of cellular redox status by saikosaponins is a common effect in cancer cells that we tested. Altogether, these results indicate that cellular ROS were strongly induced by SSa or SSd, suggesting that both these saikosaponins function as pro-oxidants in cancer cells. Figure 3 Saikosaponins induce intracellular ROS accumulation in HeLa cells. HeLa cells were treated with cisplatin (8 μM) or saikosaponin-a (10 μM) or saikosaponin-d (2 μM) individually or combination

of saikosaponin and cisplatin for 30 min. 5 μM of DHE (A) or 5 μM of CM-H2DCFDA (B) was added 30 min before collecting cells. SBE-��-CD molecular weight The fluorescent intensities of 10,000 cells were analyzed with a flow cytometer. Untreated cells with DHE or CM-H2DCDA staining were used as a negative control. The histogram overlays show the results of treated cells (red

lines) compared with untreated cells (green lines). x-axis, fluorescent intensity showing the extent of DHE or CM-H2DCFDA oxidation; y-axis, cell number. The data (mean fluorescence for each group) was also presented as bar charts below the profiles (error bars indicate SD of triplicate experiments). ROS accumulation contributes to the synergistic LY411575 datasheet cytotoxicity induced by saikosaponins plus cisplatin We next investigated whether the ROS accumulation is required for the potentiated cytotoxicity induced by saikosaponins and cisplatin Epacadostat purchase co-treatment. As shown in Figure 4A, both the ROS scavengers BHA and NAC almost completely suppressed the potentiation of cisplatin-indcued cytotoxicity by SSa. Similarly, the ROS scanvengers also effectively inhibited the enhanced cell death in SSd and cisplatin cotreated cells (Figure 4B). The inhibition effect of ROS scavengers on cell death was correlated with significant reduction of.O2 – and H2O2 levels in cells (Figure 4C and 4D). To further confirm the effect of ROS in synergistic cytotoxicity induced by saikosaponins plus cisplatin, Siha, A549, and SKOV3 cells were pretreated

with NAC and then treated with saikosaponins and cisplatin individually or both. As expected, NAC also suppressed the enhanced cell death mediated by saikosaponins and cisplatin co-treatment in these Dipeptidyl peptidase cells (Figure 5A, 5B, and 5C). These results suggest that induction of ROS is crucial for saikosaponins’ potentiation effect on cisplatin-induced cytotoxicity in cancer cells. Figure 4 ROS accumulation contributes to the synergistic cytotoxicity induced by saikosaponins plus cisplatin in HeLa cells. (A) and (B) HeLa cells were pretreated with BHA (100 μM) or NAC (1 mM) for 30 min or remained untreated and then treated with saikosaponin-a (10 μM) or saikosaponin-d (2 μM) or cisplatin (8 μM) individually or combination of saikosaponin and cisplatin for 48 h. Cell death was measured as described in Fig. 1A.

These cells occasionally displayed a stellate-shaped or fusiform architecture with cytoplasmic projections, thereby assuming a mesenchymal appearance (Fig. 3a). In these areas, some of the carcinoma cells—especially those presenting morphological alterations—co-expressed epithelial membrane antigen and α-smooth muscle actin. The former stain had a purple membranous or cytoplasmic appearance and the latter stain was brown and cytoplasmic (Fig. 3a and b). Fig. 3 a Small islands of carcinoma cells at the invading front showing a stellate-shaped and fusiform architecture with cytoplasmic projections, some with a fibroblastoid appearance.

Remnants of epithelial membrane antigen staining (purple membranous/cytoplasmic stain) mTOR inhibitor disclose their epithelial origin. Brownish cytoplasmic staining of α-smooth muscle actin is observed in a few foci within the carcinoma cells (arrows) (anti-epithelial MEK162 clinical trial membrane antigen and anti-α-smooth muscle actin antigen antibodies, Fast-red and 3,3′-diaminobenzidine (DAB) double immunostaining; bar 50 μ). b Spindle carcinoma cells with remnants of epithelial membrane antigen staining and VS-4718 price an area of brown cytoplasmic stain compatible with α-smooth

muscle actin positivity (thin arrow). A cluster of carcinoma cells negative for epithelial membrane antigen and ID-8 positive for α-smooth muscle actin is seen in the upper left corner (thick arrow) (bar 20 μ) The higher the SMF counts, the more frequent the “network” distribution of the SMF tended to be, and the more frequent the presence of carcinoma cells

co-expressing epithelial membrane antigen and α-smooth muscle actin (Table 2). Discussion The results of our study showed that presence of SMF was associated with carcinoma of the tongue, while these cells were sparse to absent in pre-malignant lesions. In addition, we found that tumors were heterogeneous in the extent of SMF and their pattern of distribution and morphological features. Indications of an association between squamous cell carcinoma and SMF were reported in previous studies that employed cell lines [25] and specimens of squamous cell carcinoma of the entire oral cavity [26, 27]. The presence of SMF was recently analyzed in a series of tongue carcinomas versus normal and dysplastic epithelial lesions from the entire oral mucosa [28]. In that study, in which frequency of SMF was assessed by a vague semi-quantitative scale, it was reported that SMF were found exclusively in carcinoma (~60%) and not in any of the dysplastic lesions. In contrast, in the present study, tongue carcinomas were analyzed versus tongue dysplastic lesions and the frequency of SMF was assessed by a systematic immunomorphometric method.

BAY 11-7082 PubMedCrossRef 22. Akman L, Yamashita A, Watanabe H, Oshima K, Shiba T, Hattori M, Aksoy S: Genome sequence of the endocellular obligate symbiont of tsetse flies, Wigglesworthia glossinidia . Nat Genet 2002, 32:402–407.PubMedCrossRef 23. Nakabachi A, Yamashita A, Toh H, Ishikawa H, Dunbar HE, Moran NA, Hattori M: The 160-kilobase genome of the bacterial endosymbiont Carsonella . Science 2006, 314:267.PubMedCrossRef 24. McCutcheon JP, McDonald BR, Moran NA: Convergent evolution of metabolic roles in bacterial co-symbionts of insects. Proc Nat Acad Sci USA 2009, 106:15394–15399.PubMedCrossRef 25. McCutcheon JP, Moran GW3965 chemical structure NA: Parallel genomic

evolution and metabolic interdependence in an ancient symbiosis. Proc Nat Acad Sci USA 2007, 104:19392–19397.PubMedCrossRef 26. Gil R, Latorre A: Factors behind junk DNA in bacteria. Genes 2012, 3:634–650.CrossRef 27. Hershberg R, Petrov DA: Evidence that mutation QNZ datasheet is universally biased towards AT in bacteria. PLoS Genet 2010, 6:e1001115.PubMedCrossRef 28. Hildebrand F, Meyer A, Eyre-Walker A: Evidence of selection upon genomic GC-content in bacteria. PLoS Genet 2010, 6:e1001107.PubMedCrossRef 29. Behrens S, Maier R, De Cock H, Schmid FX, Gross CA: The SurA periplasmic PPIase lacking its parvulin domains functions in vivo and has chaperone activity. EMBO J 2001, 20:285–294.PubMedCrossRef 30. Dermic D: Functions of

multiple exonucleases are essential for cell viability, DNA repair and homologous recombination in recD mutants of Escherichia

coli . Genetics 2006, 172:2057–2069.PubMed 31. Heller RC, Marians KJ: The disposition of nascent strands at stalled replication forks dictates the pathway of replisome loading during restart. Mol Cell 2005, 17:733–743.PubMedCrossRef 32. Xu L, Marians KJ: Purification and characterization of DnaC810, a primosomal protein capable of bypassing PriA function. J Biol Chem 2000, 275:8196–8205.PubMedCrossRef 33. Fraser CM, Gocayne JD, White O, 2-hydroxyphytanoyl-CoA lyase Adams MD, Clayton RA, Fleischmann RD, Bult CJ, Kerlavage AR, Sutton G, Kelley JM, Fritchman JL, Weidman JF, Small KV, Sandusky M, Fuhrmann J, Nguyen D, Utterback TR, Saudek DM, Phillips CA, Merrick JM, Tomb JF, Dougherty BA, Bott KF, Hu PC, Lucier TS, Peterson SN, Smith HO, Hutchison CA III, Venter JC: The minimal gene complement of Mycoplasma genitalium . Science 1995, 270:397–403.PubMedCrossRef 34. Lopper M, Boonsombat R, Sandler SJ, Keck JL: A hand-off mechanism for primosome assembly in replication restart. Mol Cell 2007, 26:781–793.PubMedCrossRef 35. Gil R, Silva FJ, Pereto J, Moya A: Determination of the core of a minimal bacterial gene set. Microbiol Mol Biol Rev 2004, 68:518–537.PubMedCrossRef 36. Quan S, Zhang N, French S, Squires CL: Transcriptional polarity in rRNA operons of Escherichia coli nus A and nus B mutant strains. J Bacteriol 2005, 187:1632–1638.PubMedCrossRef 37. Price NL, Raivio TL: Characterization of the Cpx regulon in Escherichia coli strain MC4100. J Bacteriol 2009, 191:1798–1815.PubMedCrossRef 38.

The first and second scenarios, however, appear rather unlikely, because hardly any macrophages

or monocytes were observed in histopathologic analyses at day one after infection. The third scenario appears quite likely, because histopathological analysis revealed a strong infiltration of neutrophils encasing ungerminated conidia. In contrast, functionally attenuated neutrophils and macrophages in corticosteroid-treated mice allowed development of invasive disease despite robust cellular recruitment in the lung parenchyma.   The treatment of mice with cortisone acetate or the combination of clodrolip and cortisone acetate led to 100% mortality and invasive fungal growth within the lung tissue. Although systemic administration of corticosteroids increases the number of circulating neutrophils by three- to fivefold [31], their ability to damage A. fumigatus hyphae is strongly reduced [32]. One day post-infection,

the lung tissue showed AZD2171 in vitro LY3023414 in vitro an extensive neutrophilic infiltration that surrounded germinating conidia. These neutrophils were able to delay uncontrolled tissue invasion by killing some proportion of fungal hyphae. As a consequence of the neutrophil infiltration severe tissue damage accompanied by parenchymal destruction (necrosis) was observed, leading to a decreased bioluminescence as described above. It is also noteworthy that under cortisone acetate treatment the efficiency of alveolar macrophages in inhibiting conidial germination after phagocytosis was strongly defective. None of the other treatment groups yielded hyphal germlings as early as one day post-infection. It could be assumed that this rapid germination is due to growth stimulation

via A. fumigatus corticosteroid receptors [33]. However, experiments, in which different concentrations of cortisone acetate were added to A. fumigatus cultures, neither Selleckchem VS-4718 stimulated conidia germination, nor increased the light emission (data not shown). Since Teicoplanin cortisone acetate itself constitutes an “”inactive”" corticosteroid derivative, which is converted into “”active”" cortisol during metabolism in the liver [34], it might be possible that a stimulation of germination is only mediated by this metabolite rather than by cortisone acetate. Another possibility for the rapid germination of conidia is given by a neutrophil mediated tissue destruction releasing large amounts of nutrients from tissue cells, which enhanced the germination speed under this immunosuppresive regimen. The mild inflammation under RB6-8C5 treatment one day post infection and the absence of inflammation under cyclophosphamide treatment may not provide the same nutritional conditions leading to a delayed germination when compared to the cortisone acetate treatment. Another piece of evidence that supports the dependence on the number and functional integrity of neutrophils in the clearance of A. fumigatus is the observation that RB6-8C5 treatment renders mice highly susceptible to IA.

Furthermore, the comprehensive phylogenetic analysis of tailoring enzymes such as ARO and CYC provides details about their biosynthetic function in regulation of the metabolic pathway determining click here aromatic polyketide chemotypes [4]. This finding allows us to investigate the possibility of analyzing type II PKS domain

compositions in type II PKS gene clusters with respect to aromatic polyketide chemotypes. Currently, there are several sequence-based polyketide gene cluster analysis systems for type I and type III PKSs, such as NRPS-PKS, ASMPKS, ClustScan, NP. Searcher, and antiSMASH [9–13]. Among these, antiSMASH is the only system that supports the analysis of type II PKS gene cluster. This system identifies gene clusters of type II PKS-specific domains such as KS, CLF, and ARO by using sequence-based PF-6463922 mouse classification. However, it is difficult to identify other type II PKSs and associate the gene cluster with the chemical structure of type II PKS products. Here, we performed a comprehensive computational analysis of type II PKSs and their gene clusters in actinobacterial genomes.

First, we carried out an exhaustive sequence check details analysis of known type II PKSs by using homology-based sequence clustering for the identification of type II PKS subclasses. This analysis enabled us to develop type II PKS domain classifiers and derive polyketide chemotype-prediction rules for the analysis of type II PKS gene cluster. Using these rules, we analyzed available actinobacterial genomes and predicted novel type II PKSs and PKS gene clusters together with potential bacterial aromatic polyketide chemotypes. The predicted type II PKS gene clusters were Nintedanib (BIBF 1120) verified by using information from the available

literature. All the resources, together with the results of the analysis, are organized into an easy-to-use database PKMiner, which is accessible at http://​pks.​kaist.​ac.​kr/​pkminer. Construction and content Data sources A total of 42 type II PKS gene clusters having type II PKS proteins were identified from individual literature and their sequence information was collected from the National Center for Biotechnology Information (NCBI) nucleotide database. A total of 37 bacterial aromatic polyketide chemotypes corresponding to type II PKS gene clusters were collected from literature and the NCBI pubchem database (see Additional file 1: Table S1). To fully download completely sequenced genomes from the NCBI genome database, we made custom perl script using the NCBI E-utils based on actinobacteria taxonomy. As a result, we collected a total of 319 actinobacterial genome sequences. (see Additional file 1: Table S2).

PubMedCrossRef 22. Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ: Simple methodology for the therapeutic drug monitoring of the tyrosine kinase

inhibitors dasatinib and imatinib. Biomed Chromatogr 2013, 27:335–342.PubMed 23. Burris HA III, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, et al.: A phase I and pharmacokinetic study of oral NVP-BSK805 mouse lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009, 15:6702–6708.PubMedCentralPubMedCrossRef 24. Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM: Nilotinib population pharmacokinetics and exposure-response analysis Selleck Erismodegib in patients with imatinib-resistant or -intolerant chronic

myeloid leukemia. Eur J Clin Pharmacol 2013, 69:813–823.PubMedCrossRef 25. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, et al.: Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with CP-690550 supplier advanced solid tumors. Clin Cancer Res 2012, 18:1092–1100.PubMedCrossRef 26. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R: SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008, 7:1185–1194.PubMedCentralPubMedCrossRef 27. Demetri GD, Lo RP, MacPherson IR, Wang D, Morgan JA, Brunton

VG, Paliwal P, Agrawal S, Voi M, Evans TR: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009, 15:6232–6240.PubMedCrossRef 28. Bonomi P: Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs 2003, 12:1395–1401.PubMedCrossRef Reverse transcriptase 29. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57:4838–4848.PubMed 30. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749–5754.PubMed 31. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561–566.PubMedCrossRef 32. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1:85–94.PubMed 33.

[http://​www.​cdcgov/​ncidod/​EID/​vol4no3/​relman.​htm] 1999. 33. Lancaster LE, Wintermeyer W, Rodnina MV: Colicins and their potential in cancer treatment. Volasertib order Blood Cells Mol Dis 2007, 38:15–18.PubMedCrossRef 34. Taha AS, Kelly RW, Carr G, Stiemer B, Morton R, Park RH, Beattie AD: Altered urinary this website interleukin-8/creatinine ratio in peptic ulcer disease: pathological and diagnostic implications. Am J Gastroenterol 1996, 91:2528–2531.PubMed 35. Mahida YR, Makh S, Hyde S, Gray T, Borriello

SP: Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996, 38:337–347.PubMedCrossRef 36. Castagnola E, Battaglia T, Bandettini R, Caviglia I, Baldelli I, Nantron M, Moroni C, Garaventa A: Clostridium difficile-associated disease in children with solid tumors. Support Care Cancer 2009, 17:321–324.PubMedCrossRef

37. Ellmerich S, Scholler M, Duranton B, Gosse F, Galluser M, Klein JP, Raul F: Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000, 21:753–756.PubMedCrossRef 38. Biarc J, Nguyen IS, Pini A, Gosse F, Richert S, Thierse D, Van Dorsselaer A, Leize-Wagner E, Raul F, Klein JP, et al.: Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis 2004, 25:1477–1484.PubMedCrossRef 39. Abdulamir AS, Hafidh RR, Mahdi LK, Al-jeboori T, Abubaker F: Investigation into the

controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 2009, 9:403.PubMedCrossRef 40. Abdulamir AS, Hafidh RR, Abu Bakar F: Molecular detection, quantification, and P5091 price isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer 2010, 9:249.PubMedCrossRef 41. McCoy W, Mason JM: Enterococcal endocarditis associated with Amino acid carcinoma of the sigmoid; report of a case. J Med Assoc State Ala 1951, 21:162–166.PubMed 42. Keusch GT: Opportunistic infections in colon carcinoma. Am J Clin Nutr 1974, 27:1481–1485.PubMed 43. Rusniok C, Couve E, Da Cunha V, El Gana R, Zidane N, Bouchier C, Poyart C, Leclercq R, Trieu-Cuot P, Glaser P: Genome sequence of Streptococcus gallolyticus: insights into its adaptation to the bovine rumen and its ability to cause endocarditis. J Bacteriol 2010, 192:2266–2276.PubMedCrossRef 44. Murray HW, Roberts RB: Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med 1978, 138:1097–1099.PubMedCrossRef 45. Corredoira J, Alonso MP, Coira A, Casariego E, Arias C, Alonso D, Pita J, Rodriguez A, Lopez MJ, Varela J: Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis 2008, 27:285–291.PubMedCrossRef 46. Bisno A: Streptococcal infection. In Harrison’s principles of internal medicine. 12th edition.

When the Ti-protruding dots were anodized for over 3 min, beautiful arrays of TiO2 micro-flowers successfully bloomed on the Ti foil sheets. The blooming TiO2 micro-flowers were applied as the photoelectrodes of DSCs. The J-V characteristics of the DSCs based on the TiO2 micro-flowers were compared selleckchem with those based on bare TiO2 nanotubes. The J sc and power conversion efficiency values of DSCs based on TiO2 micro-flowers were higher than those of bare samples. TiO2 micro-flowers facilitated better dye adsorption, resulting in higher J sc values. The TiO2 micro-flowers had a larger surface area for dye adsorption compared to that of bare TiO2 nanotubes. The efficiency of the DSCs based on the TiO2 micro-flowers

was found to reach 1.517%. The efficiency levels of the DSCs based on the TiO2 micro-flowers were relatively low compared to those of conventional DSCs based on TiO2 nanoparticle structures, as the

thickness of the TiO2 nanotubes in the micro-flowers was very small. To improve the efficiency of DSCs based on TiO2 micro-flowers, our future work will concentrate on controlling the characteristics of the dot patterns such as the dot diameter, the distance between adjacent dots, and the height of the protruding dots. Acknowledgements This research was financially supported by the Ministry of Education, Science, and Technology (MEST) and by the National Research Foundation of Korea (NRF) through the Human Resources Training Project for Regional Innovation IWR-1 (No. NRF-2012H1B8A2026009). References 1. Oregan B, Grätzel M: A low-cost, high-efficiency solar-cell based on dye-sensitized colloidal TiO2 films. Nature 1991,353(6346):737–740.CrossRef 2. Li L-L, Diau EW-G: Porphyrin-sensitized solar cells. Chem Soc Rev 2013,42(1):291–304.CrossRef 3. Yella A, Lee H-W, Tsao HN, Yi C, Chandiran AK, Nazeeruddin MK, Diau EW-G, Yeh C-Y, Zakeeruddin SM, Grätzel M: Porphyrin-sensitized solar cells with cobalt (II/III)-based redox electrolyte exceed 12 percent efficiency. Science 2011,334(6056):629–634.CrossRef

4. Zhu X, Tsuji HSP90 H, Yella A, Chauvin A-S, Grätzel M, Nakamura E: New sensitizers for dye-sensitized solar cells featuring a carbon-bridged phenylenevinylene. Chem Commun 2013,49(6):582–584.CrossRef 5. Marszalek M, Nagane S, Ichake A, Humphry-Baker R, Paul V, Zakeeruddin SM, Grätzel M: Structural variations of D-π-a dyes influence on the photovoltaic performance of dye-sensitized solar cells. RSC Adv 2013, 3:7921–7927.CrossRef 6. Margulis GY, Lim B, BGB324 solubility dmso Hardin BE, Unger EL, Yum J-H, Feckl JM, Fattakhova-Rohlfing D, Bein T, Grätzel M, Sellinger A: Highly soluble energy relay dyes for dye-sensitized solar cells. Phys Chem Chem Phys 2013, 15:11306–11312.CrossRef 7. Wu Y, Marszalek M, Zakeeruddin SM, Zhang Q, Tian H, Grätzel M, Zhu W: High-conversion-efficiency organic dye-sensitized solar cells: molecular engineering on D–a–π-a featured organic indoline dyes.

J Am Chem Soc 2004, 125:15269–15276.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions SK, JP, and YJ carried out the experiments.

HG and KL prepared RNA and DNA samples. SK and MS analyzed the data and drafted the manuscript. MS initiated and supervised the work. SK, KL, and MS contributed selleck chemicals llc to discussing, reviewing, and editing the manuscript before submission. SH provided the AFM results. All authors read and approved the final manuscript.”
“Background In recent years, multijunction III-V semiconductor solar cells have experienced remarkable improvements, not only for space applications but also for terrestrial concentrated photovoltaic systems. The highest photovoltaic conversion efficiency reported so far is 44.7% and has been obtained with four junction solar cell [1]. A very promising way to further improve the RG-7388 in vivo performance of solar cells is to utilize dilute nitride and dilute

antimonide materials, which can be grown lattice matched onto GaAs and Ge substrates [2]. These materials provide suitable absorption bands to harvest photons down to 1 eV and even below. Recently, a conversion efficiency of 44% was reported for a triple junction solar cell including a bottom junction based on GaInNAs(Sb) grown by molecular beam epitaxy (MBE) [3]. Adding antimony to ternary GaAsN to form GaAsNSb compounds can be also used to lower the bandgap beyond the 1-eV limit, serving as an alternative to quinary alloys, which

are somewhat more difficult to grow due to the presence of three elements of group V [4, 5]. The drawback in using dilute nitrides/antimonides is related to challenges in material selleck fabrication [6] and formation new of defects [7, 8]. Careful growth parameter optimization and thermal annealing are known to increase the material quality and carrier lifetimes [9]. Carrier lifetime correlates with solar cell performance via the minimum diffusion length required for the carriers to travel without recombination, and it should be maximized in order to harvest efficiently the photogenerated carriers [10]. Time-resolved photoluminescence (TRPL) using up-conversion technique [11] is commonly used for estimating carrier lifetimes of optoelectronic heterostructures and has been extensively used in connection with optimization of GaInNAs heterostructures [2, 12–14]. However, most of the studies have been concerned with analyses of quantum wells [15]. Studies on GaInAsN epilayers have reported a wide variety of lifetimes in the range of 70 to 740 ps [8, 16]. In this paper, we report TRPL values for bulk GaInAsN and GaNAsSb p-i-n solar cells. In particular, we focus on correlating the effects of thermal annealing and the nitrogen composition. Methods The samples studied were grown on GaAs(100) substrate by MBE equipped with radio-frequency plasma source for atomic nitrogen incorporation. Their structures are presented in Figure 1.

For λ < approximately 450 nm, the efficiency enhancement could now be regarded as wholly from the contribution of PL conversion, since the reflectance coefficients at C QD = 0 and 1.6 mg/ml are nearly the same as shown in Figure 3b. Hence, the PL contribution was calculated as the area difference between C QD = 1.6 mg/ml and 0 for λ < approximately 450 nm only, divided by the whole area for C QD = 0. It was 1.04%. Therefore, the rest 5.96% − 1.04% = 4.92% was due to AR. In Figure 5, I-V curves for

bare Si solar cell and Si solar cell coated with QD-doped PLMA (C QD = 0 and 1.6 mg/ml) are depicted. U OC and FF change slightly; only the I SC varies steadily, leading to a change in η. In SBI-0206965 Table 1, Δη/η 0 for C QD = 3.0 mg/ml is as high as 9.97%, which is the highest efficiency enhancement achieved in this work. However, from Figure 3a, it is certain that the PL contribution to Δη/η 0 at C QD = 3.0 mg/ml is very little. The AR effect

contributes dominantly, which could be attributed to the modification of refractive index gradient [19]. Since many other efficient AR approaches have been developed [19–22], the effect of AR will not be further discussed here. Figure 4 EQE curves and emission spectrum of the standard AM0. EQE curves for Si solar cells coated with QD-doped PLMA with C QD = 0 and 1.6 mg/ml (right ordinate) and the power-density-normalized Ferrostatin-1 solubility dmso standard AM0 spectrum (left ordinate). The dotted curve is the modified EQE curve for C QD = 0 (right ordinate) under the AM0 condition. Figure 5 I-V curves. For bare Si solar cell and Si solar cells coated with QD-doped PLMA at C QD = 0 and 1.6 mg/ml. Table 1 PV

parameters for Si solar cells after treatments Sample I SC(mA) U OC(V) FF (%) η (%) Δ η /η 0(%) Δ η /η 0(%) (calculated) Bare cell 66.50 0.59 73.65 11.12 – - C QD = 0 74.74 0.59 73.78 12.54 0.00 0.00 C QD = 1.6 mg/ml 78.10 0.59 74.38 Rucaparib price 13.24 5.58 5.96 C QD = 3.0 mg/ml 81.08 0.60 74.50 13.79 9.97 – In this work, AM0 solar MK-1775 simulator rather than the more conventional AM1.5 one has been used. This is because the effect of PL conversion on the performance improvement of solar cell is more applicable in the environment with higher UV proportions. The UV proportion in the high altitude or outer space environment, which the AM0 condition mimics, is generally two to three times that in the normal AM1.5 one. On the other hand, from Figure 4, it is seen that the solar cell has high EQE in a broad wavelength range of approximately 450 to 1,000 nm; therefore, although for each wavelength, the corresponding reflectance changes with the changing film thickness due to the light interference, the overall efficiency enhancement is not sensitive to the film thickness, as what we found in our experiments for the film thickness in the range of 100 to 300 nm.